BioCentury
ARTICLE | Clinical News

GEN-004: Phase IIa started

September 22, 2014 7:00 AM UTC

Genocea began a double-blind, placebo-controlled, U.K. Phase IIa trial to evaluate 100 Ug intramuscular GEN-004 every 4 weeks for up to 3 doses with a 350 Ug aluminum hydroxide adjuvant in about 90 he...